These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30008760)

  • 1. Insulin Monotherapy Versus Insulin Combined with Other Glucose-Lowering Agents in Type 2 Diabetes: A Narrative Review.
    Abdi H; Azizi F; Amouzegar A
    Int J Endocrinol Metab; 2018 Apr; 16(2):e65600. PubMed ID: 30008760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.
    Vos RC; van Avendonk MJ; Jansen H; Goudswaard AN; van den Donk M; Gorter K; Kerssen A; Rutten GE
    Cochrane Database Syst Rev; 2016 Sep; 9(9):CD006992. PubMed ID: 27640062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complementing insulin therapy to achieve glycemic control.
    Barnett AH
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes.
    Lau DC; Teoh H
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S148-54. PubMed ID: 26654858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
    He YL
    Clin Pharmacokinet; 2012 Mar; 51(3):147-62. PubMed ID: 22339447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus.
    Madsen KS; Kähler P; Kähler LKA; Madsbad S; Gnesin F; Metzendorf MI; Richter B; Hemmingsen B
    Cochrane Database Syst Rev; 2019 Apr; 4(4):CD012368. PubMed ID: 30998259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective.
    Neeser K; Lübben G; Siebert U; Schramm W
    Pharmacoeconomics; 2004; 22(5):321-41. PubMed ID: 15061682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AHRQ's comparative effectiveness research on oral medications for type 2 diabetes: a summary of the key findings.
    Bennett WL; Balfe LM; Faysal JM
    J Manag Care Pharm; 2012; 18(1 Suppl A):1-22. PubMed ID: 22313233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials.
    Zaccardi F; Dhalwani NN; Dales J; Mani H; Khunti K; Davies MJ; Webb DR
    Diabetes Obes Metab; 2018 Apr; 20(4):985-997. PubMed ID: 29205774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
    Fass AD; Gershman JA
    Adv Ther; 2013 Apr; 30(4):337-53. PubMed ID: 23605247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: a systematic review and mixed-treatment comparison meta-analysis.
    McIntosh B; Cameron C; Singh SR; Yu C; Dolovich L; Houlden R
    Open Med; 2012; 6(2):e62-74. PubMed ID: 23696771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea.
    Lozano-Ortega G; Goring S; Bennett HA; Bergenheim K; Sternhufvud C; Mukherjee J
    Curr Med Res Opin; 2016 May; 32(5):807-16. PubMed ID: 26700585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pioglitazone, rosiglitazone, and rosiglitazone + metformin: new drugs. Glitazone + oral antidiabetic combination: inadequately evaluated.
    Prescrire Int; 2005 Aug; 14(78):133-9. PubMed ID: 16106595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New drugs for type 2 diabetes mellitus: what is their place in therapy?
    Krentz AJ; Patel MB; Bailey CJ
    Drugs; 2008; 68(15):2131-62. PubMed ID: 18840004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
    Charbonnel B; Schweizer A; Dejager S
    Hosp Pract (1995); 2013 Apr; 41(2):93-107. PubMed ID: 23680741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
    Kumar A
    Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.